Q-omics provides the consensus-scored TRMU profile across patient tissues and cancer cell-line models. TRMU expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRMU is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TRMU protein abundance shows 30,241 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where TRMU shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMU — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMU survival associations across molecular data types. TRMU RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMU RNA expression–survival associations across cancer types. High TRMU expression shows unfavorable associations in KIRC, ACC, LIHC and UVM, but favorable associations in READ and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRMU RNA expression.
This table summarizes TRMU tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRMU. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMU shows higher tumor expression in HNSC, BLCA, KIRC, COAD, LIHC and STAD. The HNSC box plot shows higher TRMU RNA expression in tumor versus normal tissue (log2 FC = +1.072, t-test p < 0.001).
This table shows molecular features associated with TRMU in patient tissues and cancer cell lines. In patient samples, TRMU shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMU RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
